New research by scientists at the University of Toronto and the Structural Genomics Consortium has deepened our understanding ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

Researchers at Novartis BioMedical Research in the US and Switzerland have identified a molecular target that may provide a ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y22 ...

The KRAS G12D mutation is the most common oncogenic KRAS variant, identified in approximately 34% of pancreatic ductal adenocarcinoma cases, 12% of colorectal cancers and 4% of lung adenocarcinomas.

A UC Davis study found that deleting a cluster of genes in wheat may reduce wheat allergies without harming breadmaking.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA Ph: +1-203-852-6800, 800-243-6002 ...

Egg whites, known for their high-quality protein content, also contain various bioactive peptides ... as effective natural antihypertensive agents. By modulating the RAS, enhancing eNOS expression, ...